Investor Andera Partners
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Andera Partners . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2025-08-14 13G/A IVA / Inventiva S.A. - Depositary Receipt (Common Stock) 6,148,147 12,296,295
2025-08-14 13G/A MLYS / Mineralys Therapeutics, Inc. 2,865,976 2,765,976
2025-04-14 13G IVA / Inventiva S.A. - Depositary Receipt (Common Stock) 6,148,147
2023-02-24 13G MLYS / Mineralys Therapeutics, Inc. 2,865,976
2022-10-20 13G/A LOGC / ContextLogic Holdings Inc. 1,787,913 2,287,413
2021-02-12 13G/A LOGC / ContextLogic Holdings Inc. 1,787,913
2021-02-03 13D/A AXNX / Axonics, Inc. 2,657,461 1,987,282
2020-05-21 13D/A AXNX / Axonics, Inc. 2,957,461 2,657,461
2020-02-05 13G/A VRNA / Verona Pharma plc - Depositary Receipt (Common Stock) 6,652,398 2,348,814
2020-01-24 13D/A AXNX / Axonics, Inc. 3,257,461 2,957,461
2019-12-03 13D/A AXNX / Axonics, Inc. 3,557,461 3,257,461
2019-02-11 13G/A VRNA / Verona Pharma plc - Depositary Receipt (Common Stock) 6,652,398
2018-12-21 13D AXNX / Axonics, Inc. 3,557,461